Antibody

New data: AstraZeneca’s COVID-19 antibody Evusheld confers 83% protection at six months … Simple test in certain pneumonia patients could help cut broad-spectrum antibiotics use … Faster onset of...

Prebreakthrough index RBD values of <10 and 10 to <23 associated with increased odds of breakthrough infection versus value of ≥23

Current antibody treatments may not protect against omicron variant, but new drugs are in development … Duodopa improves quality of life in late-stage Parkinson’s disease … CDC pours $22M into fighting...

Industry geriatricians have compiled resources for their LTC peers who have not yet come on board with monoclonal antibody treatments. Resident immunity to COVID-19 is declining, and mAbs may prevent hospital...

U.S. to limit states’ access to COVID antibody treatments as demand rises … Aggressively reducing Alzheimer’s risk factors could mean 1.2 million fewer cases in 2050: experts … NIH launches nationwide...

Johnson & Johnson’s single-shot COVID-19 vaccine prompts a “strong neutralizing antibody response” that lasts at least eight months, the drugmaker has announced.

NIH spotlights promising nasal spray antibody treatment for COVID … Anticoagulation therapy linked to lower COVID death rates: study … Spurned LTC pharmacies push again to receive Provider Relief Funds...

An antibody cocktail that halts disease progression in sick COVD-19 patients has been shown to prevent the disease altogether in healthy people who live in close contact with an infected person, the drugmaker...

New CDC data: Osteoporosis rates increase in women … Exposed to COVID? Study finds point-of-care antibody tests highly effective at detection … Ruined J&J coronavirus vaccine doses are not in circulation:...

U.S. distribution of an infusion treatment using bamlanivimab only has been halted due to virus variant concerns, but an alternative antibody cocktail from the drugmaker can still be ordered, according...